Michael Bolaris to Cost-Benefit Analysis
This is a "connection" page, showing publications Michael Bolaris has written about Cost-Benefit Analysis.
Connection Strength
0.370
-
Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin. Clin Microbiol Infect. 2021 Sep; 27(9):1346.e1-1346.e7.
Score: 0.173
-
Early onset sepsis calculator-based management of newborns exposed to maternal intrapartum fever: a cost benefit analysis. J Perinatol. 2019 04; 39(4):571-580.
Score: 0.153
-
'Cost-benefit analysis comparing trough, two-level AUC, and Bayesian AUC dosing for vancomycin': authors' reply. Clin Microbiol Infect. 2021 06; 27(6):929-930.
Score: 0.044